Acute Bacterial Skin And Skin Structure Infections Market Report 2026

Acute Bacterial Skin And Skin Structure Infections Market Overview

• Acute Bacterial Skin And Skin Structure Infections market size has reached to $12.9 billion in 2025 • Expected to grow to $20.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Elevated Prevalence Of Skin Infections Fuels Growth In The Acute Bacterial Skin And Skin Structure Infections Market • Market Trend: Innovative Single Dose Therapies Transforming The Acute Bacterial Skin And Skin Structure Infection Treatment • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Acute Bacterial Skin And Skin Structure Infections Market?

Acute bacterial skin and skin structure infections (ABSSSIs) are a type of skin infection caused by bacteria that affect the skin and underlying tissues, leading to symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, such as antibiotic treatment, are used to prevent complications and promote healing in mild to severe infections. The main types of acute bacterial skin and skin structure infections are hospital-acquired acute bacterial skin and skin structure infections and community-acquired acute bacterial skin and skin structure infections. Hospital-acquired acute bacterial skin and skin structure infections are infections of the skin and underlying tissues that develop as a result of medical care or hospitalization. The types of active ingredients include delafloxacin, vancomycin, ceftaroline fosamil, oritavancin, tedizolid, daptomycin, tigecycline, linezolid, and others, and can be administered through several routes, such as oral, parenteral, and topical. These are sold through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for various applications, including cellulitis, abscesses, surgical wounds, and traumatic wounds.

What Is The Acute Bacterial Skin And Skin Structure Infections Market Growth Forecast?

The acute bacterial skin and skin structure infections market size is expected to see rapid growth in the next few years. It will grow to $20.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of next-generation antibiotics, increasing investments in antimicrobial research, growing community-based infection management programs, expansion of hospital pharmacy distribution channels, implementation of rapid diagnostic technologies. Major trends in the forecast period include rising incidence of acute bacterial skin and skin structure infections, growing adoption of novel antibiotics and combination therapies, expansion of hospital and community healthcare facilities, increasing use of oral and parenteral antibiotics, focus on reducing hospital-acquired infection rates.

Global Acute Bacterial Skin And Skin Structure Infections Market Segmentation

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections 2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients 3) By Route Of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices 2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

What Is The Driver Of The Acute Bacterial Skin And Skin Structure Infections Market?

The rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market going forward. Skin infections are conditions in which microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. The rise in skin infections creates a greater demand for therapeutic solutions, antibiotics, and innovative treatments to address acute bacterial and skin structure infections, ensuring patients can access the best possible care and outcomes. For instance, in March 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, about 1.8 billion people globally suffer from skin conditions at any time. Neglected tropical diseases (NTDs) make up around 10% of these, with fungal infections at 34% and bacterial infections at 23%, often leading to high mortality rates. Therefore, the rising prevalence of skin infections will drive the growth of the acute bacterial skin and skin structure infections industry.

Key Players In The Global Acute Bacterial Skin And Skin Structure Infections Market

Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group

Global Acute Bacterial Skin And Skin Structure Infections Market Trends and Insights

Major companies operating in the acute bacterial skin and skin structure infections market are focused on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge in the market. Dalbonova is a single-dose therapy that provides convenience and effectiveness so patients can achieve their desired results with just one potent 1500 mg dose administered once. For instance, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company that focuses on API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection reduces the risk of hospital-acquired diseases by offering a single-dose treatment and eliminating the need for hospital admissions. It is designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in patients of all ages, including newborns.

What Are Latest Mergers And Acquisitions In The Acute Bacterial Skin And Skin Structure Infections Market?

In July 2023, Melinta Therapeutics, a US-based pharmaceutical company, in partnership with the Biomedical Advanced Research and Development Authority, to advance two FDA-approved antibiotics, Baxdela and Minocin, for use in pediatric patients. With this partnership, Merck aims to enhance its pipeline in haematology by leveraging Imago BioSciences' innovative therapies for myeloproliferative neoplasms and other bone marrow diseases, expanding its capabilities to deliver breakthrough treatments to patients suffering from these severe conditions. Biomedical Advanced Research and Development Authority is a US-based government agency that develops and acquires medical countermeasures to protect the United States from public health threats.

Regional Outlook

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Bacterial Skin And Skin Structure Infections Market?

The acute bacterial skin and skin structure infections market consists of revenues earned by entities by providing services such as diagnostic testing, surgical procedures for abscess drainage or debridement, inpatient and outpatient healthcare services, and home healthcare and wound care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute bacterial skin and skin structure infections market also includes sales of wound dressings and bandages, medical devices for wound care, vaccines, hydrogen peroxide, and fusidic acid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Bacterial Skin And Skin Structure Infections Market Report 2026?

The acute bacterial skin and skin structure infections market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute bacterial skin and skin structure infections industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.